Bioton SA BIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 48.45
- Price/Sales
- 1.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 359
- Website
- http://www.bioton.pl
Comparables
Valuation
Metric
|
BIO
|
CLN
|
300108
|
---|---|---|---|
Price/Earnings (Normalized) | 48.45 | — | — |
Price/Book Value | 0.50 | 1.72 | — |
Price/Sales | 1.66 | 4.65 | 3.12 |
Price/Cash Flow | 8.63 | 37.86 | — |
Price/Earnings
BIO
CLN
300108
Financial Strength
Metric
|
BIO
|
CLN
|
300108
|
---|---|---|---|
Quick Ratio | 0.29 | 1.89 | 0.10 |
Current Ratio | 1.01 | 2.20 | 0.25 |
Interest Coverage | 1.88 | −6.64 | 0.01 |
Quick Ratio
BIO
CLN
300108
Profitability
Metric
|
BIO
|
CLN
|
300108
|
---|---|---|---|
Return on Assets (Normalized) | −2.10% | −7.54% | −11.67% |
Return on Equity (Normalized) | −2.83% | −9.77% | — |
Return on Invested Capital (Normalized) | −1.54% | −8.88% | −11.91% |
Return on Assets
BIO
CLN
300108
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ddgnwqkcf | Syr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Btmntwvw | Cwgsxvz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kbcyszrsb | Fhqdp | $97.8 Bil | |
MRNA
| Moderna Inc | Mgtqswf | Fvc | $38.8 Bil | |
ARGX
| argenx SE ADR | Tdkyfwtw | Xhpj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Fmggnkfr | Wqpd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bqwxpzrh | Lwpklc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ssqtdfpkl | Jxjxpd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yktgmtmwl | Rgrjk | $12.5 Bil | |
INCY
| Incyte Corp | Zppvzfyv | Xrjzj | $11.5 Bil |